30.04.2015 • NewsDede Willamsgeneric drugsgenerics

Mylan Sweetens its Bid for Perrigo

Still being pursued by Israeli generics giant Teva, Netherlands-based drugmaker Mylan has increased its offer to acquire the issued and to-be-issued shares of smaller generics producer Perrigo.

Under the terms of the sweetened offer, Perrigo shareholders would receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share. Altogether, analysts said the total per share value is $232.2l, about 25 times the company's 2014 EBITDA (pro forma for Perrigo's recent acquisition of Omega Pharma).

Goldman, Sachs & Co., as financial advisor to Mylan, said it is satisfied that the company has sufficient resources to satisfy in full the cash consideration payable upon full acceptance of offer.

Mylan's executive chairman Robert J. Coury called the proposed deal a "truly compelling combination, which is a win-win for both Mylan and Perrigo shareholders and all other stakeholders."

If the deal goes ahead, Mylan shareholders would own about 60.7% of the outstanding Mylan ordinary shares on a fully diluted basis, and former Perrigo shareholders would own approximately 39.3% of the outstanding Mylan ordinary shares on a fully diluted basis.

Mylan's board has unanimously rejected Teva's more than $40 billion offer, which is contingent on the Perrigo transaction not being consummated. Perrigo's board previously rejected Mylan's bid.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read